Acute leukemia arising from a myelodysplastic syndrome after long-term administration of iproplatin.
BACKGROUND
Iproplatin (cis-dichloro-transdihydroxybis-isopropylamine platinum IV; CHIP) is a second generation cisplatin derivative that was developed to retain the antineoplastic effect of cisplatin with fewer toxic effects. Early clinical studies showed moderate activity in some neoplasms, with disappointing results in tumors of the lower gastrointestinal tract. Myelosuppression was the dose-limiting toxic effect in the acute setting.


METHODS
The authors report a patient with metastatic adenocarcinoma of the colon who received long-term therapy with CHIP.


RESULTS
The patient achieved complete remission of disease after prolonged treatment with CHIP. The patient subsequently had a myelodysplastic syndrome that rapidly transformed to acute myelogenous leukemia.


CONCLUSIONS
Acute leukemia may represent a late complication of CHIP therapy.
Lemke
S M
SM
Department of Medicine, SUNY Health Science Center, Syracuse 13210.
Graziano
S
S
Cho
C
C
Poiesz
B J
BJ
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001344:Autopsy; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D016609:Neoplasms, Second Primary; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C023359:iproplatin